Monitoring of atherogenicity. The patient’s plasma was subjected to 2-hour extracorporeal perfusion through a column with 200 mL of the sorbent; the flow rate was 30 mL/min. The total plasma volume of 2-3 liters was perfused during the procedure. The serum atherogenicity after 3 procedures was assessed daily ((a), patient 3) and once or twice a week afterwards ((b), patient 1). Ordinate (atherogenicity), % of cholesterol accumulation in the cells cultured in the presence of the serum from the CHD patient.